Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEGI.L Regulatory News (EGI)

  • There is currently no data for EGI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

$1.75m Phase II SBIR grant from NINDS/NIH

15 Jul 2014 07:00

RNS Number : 2815M
Electrical Geodesics, Inc
15 July 2014
 



 

Electrical Geodesics, Inc.

 

$1.75m Phase II SBIR grant from NINDS/NIHto develop MRI compatible "Ink Net" EEG electrode technology

 

 

 

EUGENE, OREGON, US, [ 15 July 2014] - Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, today announces the award of a $1.75 million SBIR grant from the US National Institute of Neurological Disorders and Stroke/National Institutes of Health ("NINDS/ NIH") to support the development of a revolutionary technology to perform dense-array EEG within high-field MRI settings.

 

Simultaneous use of dense-array EEG with MRI scanning is becoming increasingly important in both the scientific understanding of neurophysiology in managing conditions such as epilepsy and the non-invasive, pre-surgical planning for brain surgery. Typically, EEG electrodes are connected with metallic wires that interfere with the magnetic field within the MR scanners, increasing the risk of tissue heating, causing errors and artefacts in the highly sensitive dEEG recordings and MR images.

 

EGI has prototyped the use of an "Ink Net" design using customised high-resistive conductive inks printed on polymer film to connect electrodes to the EEG amplifier. These polymer inks have the potential to deliver the required quality of signal with minimal interference with the magnetic fields. Working with Massachusetts General Hospital ("MGH"), EGI will use this grant funding over the next 2 to 3 years to refine the development and validation of its Geodesic Sensor Net technology to create a range of Ink Net products for clinical and research use.

 

 

Don Tucker, PhD, Chairman and CEO of EGI, said:

 

"We have a number of on-going collaborations with neurologists and neurosurgeons both in the US and internationally which demonstrate the value of dense-array EEG alongside MR imaging in delivering accurate images of the electrical activity of the brain. Better technologies are needed to optimize the use of the tools already available to the neuroscience community and the award of this grant and support of experts at MGH will allow us to research and prove new substrates and inks and develop and validate the next generation of EEG signal technology."

 

 

For more information contact:

 

EGI

UK: Christine Soden, CFO

+44 (0) 7710 484199

Peel Hunt LLP (NOMAD and Broker)

+44 (0) 20 7418 8900

James Steel, Clare Terlouw

FTI Consulting (PR Advisors)

+44 (0) 20 7831 3113

Simon Conway, Mo Noonan

 

 

Notes to Editors

 

Electrical Geodesics, Inc. in Summary

 

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

 

EGI's dEEG systems, available in the GES 300 and now the GES 400 lines, capitalise on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).

 

See our website www.egi.com

 

Glossary

EEG

Electroencephalography

dEEG

Dense-array EEG

MRI

Magnetic resonance imaging

fMRI

Functional MRI

PET

Positron emission tomography

MEG

Magneto encephalography

NIRS

Near-infra-red spectroscopy

TES

Trans-cranial electrical stimulation

TMS

Trans-cranial magnetic stimulation

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUSRNRSWABAAR
12
Date   Source Headline
28th Mar 20147:00 amRNSAnnual Financial Report
26th Feb 20147:00 amRNSFinal Results
21st Feb 20147:00 amRNSRegulatory Approval
25th Nov 20137:00 amRNSTrading Statement
1st Oct 20137:00 amRNSAcquisition
4th Sep 20137:00 amRNSAppointment of Non-executive Director
4th Sep 20137:00 amRNSHalf Yearly Report
23rd Jul 20137:00 amRNSTrading Update
29th May 20137:00 amRNSCollaboration with Hitachi
17th May 20137:04 amRNSProduct Launch
8th Apr 20133:41 pmRNSHolding(s) in Company
5th Apr 20133:31 pmRNSHolding(s) in Company
3rd Apr 20137:01 amRNSEGI commences trading on AIM
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.